



|                      |   |                 |
|----------------------|---|-----------------|
| <b>03.03.2025</b>    |   |                 |
| <b>11:30 - 12:30</b> | <b>Type: Industry Satellite Symposium</b><br><b>Title: Industry satellite symposium 1</b>   | <b>Scene AB</b> |
| <b>12:30 - 13:05</b> | <b>Type: Break</b><br><b>Title: Welcome reception</b>   | <b>Foyer</b>    |
| <b>13:05 - 13:40</b> | <b>Type: Keynote address</b><br><b>Title: Welcome to ESMO TAT 2025 and Honorary Award</b><br><br>Moderation: Elena Garralda, Spain; Cristian Massacesi, United States of America; Anastasios Stathis, Switzerland   | <b>Scene AB</b> |
| 13:05 - 13:10        | <b>Welcome to ESMO TAT 2025</b><br><br><u>Elena Garralda</u> <sup>1</sup> , <u>Cristian Massacesi</u> <sup>2</sup> , <u>Anastasios Stathis</u> <sup>3</sup> , <sup>1</sup> Vall d'Hebron University Hospital, Barcelona, Spain, <sup>2</sup> AstraZeneca Pharmaceuticals LP, Gaithersburg, United States of America, <sup>3</sup> EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland |                 |
| 13:10 - 13:15        | <b>Introduction to the ESMO TAT 2025 Honorary Awardee</b>   |                 |
| 13:15 - 13:40        | <b>ESMO TAT 2025 Honorary award keynote lecture (To be announced)</b>   |                 |
| <b>13:45 - 15:15</b> | <b>Type: Special session with Industry</b><br><b>Title: Novel combinations in molecular oncology: Bench to bedside to the regulator</b><br><br>Moderation: Timothy Anthony Yap, United States of America; Cristian Massacesi, United States of America  | <b>Scene AB</b> |
| 13:45 - 14:00        | <b>Preclinical model-based PK/PD approaches for optimising combination therapies</b><br><u>Megan Gibbs</u> , AstraZeneca, Waltham, United States of America   |                 |
| 14:00 - 14:15        | <b>Early clinical strategies and Project Optimus considerations for novel-novel drug combinations</b><br><u>Timothy Anthony Yap</u> , The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America  |                 |
| 14:15 - 14:30        | <b>Key ingredients to getting a drug combination approved: Industry perspective</b><br><u>Marjorie Green</u> , Merck & Co, Rahway, United States of America   |                 |
| 14:30 - 14:45        | <b>Regulatory perspectives and considerations for novel combination drug approval</b><br><u>Sinan Sarac</u> , Parexel Denmark A/S, Hoersholm, Denmark   |                 |
| 14:45 - 15:15        | <b>Panel discussion</b>   |                 |



|                      |  |                 |
|----------------------|--|-----------------|
| <b>15:15 - 15:45</b> | <b>Type: Break</b><br><b>Title: Coffee break</b>                                   | <b>Foyer</b>    |
| <b>15:45 - 17:15</b> | <b>Type: Abstract session</b><br><b>Title: Abstract session 1</b>                  | <b>Scene AB</b> |
| <b>17:15 - 18:15</b> | <b>Type: Poster Display session</b><br><b>Title: Poster Display &amp; Cocktail</b> | <b>Foyer</b>    |



04.03.2025

**08:00 - 08:45**      **Type: Workshop**      **Loft GH**  
**Title: Workshop in collaboration with ESMO YOC: Using AI to write a paper/grant application: Do's and don'ts**  
Moderation: Andre Freitas, United Kingdom; Kok Haw Jonathan Lim, United Kingdom

08:00 - 08:00      **YO Coordinators**  
Elene Mariamidze<sup>1</sup>, Rille Pihlak<sup>2</sup>, <sup>1</sup>Todua Clinic, Tbilisi, Georgia, <sup>2</sup>St. Bartholomew's Hospital - Barts Health NHS Trust, London, United Kingdom

08:00 - 08:10      **Explainable AI: How can this be used for grant writing?**  
Andre Freitas, Cancer Research UK Manchester Institute - The University of Manchester, Macclesfield, United Kingdom

08:10 - 08:20      **AI to write a paper/grant: Practical hints and tips**  
Kok Haw Jonathan Lim, The Francis Crick Institute, London, United Kingdom

08:20 - 08:45      **Q&A and discussion**

**08:45 - 10:15**      **Type: Educational session**      **Loft ABDE**  
**Title: Liquid biopsy applications**  
Moderation: Klaus Pantel, Germany

08:45 - 09:05      **Liquid biopsy: Biological considerations and implementation challenge**  
Klaus Pantel, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany

09:05 - 09:25      **Computational techniques to improve sensitivity and specificity for cfDNA assays**  
Anders Skanderup, A\*STAR - Genome Institute of Singapore (GIS), Singapore, Singapore

09:25 - 09:45      **ctDNA for MRD vs conventional surveillance in adjuvant CRC: Either/or? Both?**  
Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, Australia

09:45 - 10:05      **Driving towards personalised medicine in GU malignancies**  
Benjamin Garmezzy, Sarah Cannon Research Institute, Nashville, United States of America

10:05 - 10:15      **Q&A and discussion**

**08:45 - 10:15**      **Type: Educational session**      **Scene AB**  
**Title: Bispecific antibodies for immuno-oncology**  
Moderation: Juanita Lopez, United Kingdom; Victor Moreno Garcia, Spain

08:45 - 09:05      **NK cell bispecific engagers**  
Juanita Lopez, The Royal Marsden Hospital NHS Foundation Trust, Sutton, United Kingdom



|                      |   |                  |
|----------------------|---|------------------|
| 09:05 - 09:25        | <b>Gamma-delta T cell activating bispecifics</b><br><u>Natalie Mount</u> , Abingworth LLP, London, United Kingdom   |                  |
| 09:25 - 09:45        | <b>Blocking the 'don't eat me' cascade by CD47 targeting</b><br><u>Matteo Simonelli</u> , Humanitas University, Pieve Emanuele, Italy   |                  |
| 09:45 - 10:05        | <b>Dual bispecific combination strategies therapy to overcome evolving resistance</b><br><u>Martijn Lolkema</u> , Amgen Europe B.V., Breda, Netherlands   |                  |
| 10:05 - 10:15        | <b>Q&amp;A and discussion</b>   |                  |
| <b>10:15 - 10:45</b> | <b>Type: Break</b><br><b>Title: Coffee break</b>  | <b>Foyer</b>     |
| <b>10:45 - 12:15</b> | <b>Type: Special session with Industry</b><br><b>Title: Investigator initiated trials: The osmosis with sponsors, regulators, trialists</b><br>Moderation: <u>Theresa Kolben</u> , Germany; <u>Anastasios Stathis</u> , Switzerland | <b>Scene AB</b>  |
| 10:45 - 10:50        | <b>Introduction</b><br><u>Anastasios Stathis</u> , EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland  |                  |
| 10:50 - 11:05        | <b>The pharma perspective</b><br><u>Theresa Kolben</u> , Bayer AG, Leverkusen, Germany  |                  |
| 11:05 - 11:20        | <b>The investigator perspective</b><br><u>Irene Braña</u> , Vall d'Hebron University Hospital, Barcelona, Spain   |                  |
| 11:20 - 11:35        | <b>The patient perspective</b><br><u>Bettina Ryll</u> , Melanoma Patient Network Europe MPNE, Uppsala, Sweden   |                  |
| 11:35 - 11:50        | <b>The view of the cooperative groups</b><br><u>Denis Lacombe</u> , EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, Belgium  |                  |
| 11:50 - 12:15        | <b>Panel discussion</b>   |                  |
| <b>10:45 - 12:15</b> | <b>Type: Educational session</b><br><b>Title: Cell therapies in solid tumours</b><br>Moderation: <u>Victor Moreno Garcia</u> , Spain; <u>Fiona Thistlethwaite</u> , United Kingdom  | <b>Loft ABDE</b> |
| 10:45 - 11:05        | <b>CART for solid tumours: Reality or dream?</b><br><u>Fiona Thistlethwaite</u> , The Christie NHS Foundation Trust, Manchester, United Kingdom   |                  |



- 11:05 - 11:25 **Off the shelf cell therapy: Are NK cells the better option?**  
Ulrike Köhl, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany
- 11:25 - 11:45 **2025: The year for modified TCRs for solid tumours**  
Victor Moreno Garcia, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
- 11:45 - 12:05 **Novel approaches to TIL therapy**  
Elena Garralda, Vall d'Hebron University Hospital, Barcelona, Spain
- 12:05 - 12:15 **Q&A and discussion**

**12:15 - 13:15** **Type: Break** **Foyer**  
**Title: Lunch**

**12:30 - 13:15** **Type: Workshop** **Loft GH**  
**Title: Workshop in collaboration with ESMO YOC: Basics on PKs**  
Moderation: Shelby Barnett, United Kingdom; Tim Schutte, Netherlands

12:30 - 12:30 **YO Coordinators**  
Elene Mariamidze<sup>1</sup>, Rille Pihlak<sup>2</sup>, <sup>1</sup>Todua Clinic, Tbilisi, Georgia, <sup>2</sup>St. Bartholomew's Hospital - Barts Health NHS Trust, London, United Kingdom

12:30 - 12:40 **Why do we need to understand PK curves, halfives and AUCs in early drug development?**  
Shelby Barnett, Newcastle University, Newcastle upon Tyne, United Kingdom

12:40 - 12:50 **Do we need to adjust dosing of oncolytics for young, elderly, obese, bariatric surgery, ... patients?**  
Tim Schutte, Amsterdam UMC, locatie VUmc, Amsterdam, Netherlands

12:50 - 13:15 **Q&A and discussion**

**13:15 - 14:15** **Type: Industry Satellite Symposium** **Scene AB**  
**Title: Industry satellite symposium 2**

**14:25 - 14:55** **Type: Keynote address** **Scene AB**  
**Title: Revolutionising cancer treatment: The transformative odyssey of tumor-agnostic drug development in precision medicine**  
Moderation: Anastasios Stathis, Switzerland

14:25 - 14:30 **Introduction to the Keynote Speaker**  
Anastasios Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

14:30 - 14:55 **Revolutionising cancer treatment: The transformative odyssey of tumor-agnostic drug development in precision medicine**  
Vivek Subbiah, Sarah Cannon Research Institute, Nashville, United States of America



|                      |   |                  |
|----------------------|---|------------------|
| <b>15:00 - 16:30</b> | <b>Type: Educational session</b><br><b>Title: MAPkinase</b><br>Moderation: Alex A. Adjei, United States of America; Neeltje Steeghs, Netherlands  | <b>Loft ABDE</b> |
| 15:00 - 15:20        | <b>KRAS G12C inside and outside of lung cancer</b><br><u>Alex A. Adjei</u> , Cleveland Clinic Main Campus, Cleveland, United States of America  |                  |
| 15:20 - 15:40        | <b>MAP2K4 a new kid on the KRAS block?</b><br><u>Lars Zender</u> , University Clinic Tübingen, Tuebingen, Germany   |                  |
| 15:40 - 16:00        | <b>Combinations within the MAPkinase pathway: Does drugging within the same pathway work?</b><br><u>Neeltje Steeghs</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands  |                  |
| 16:00 - 16:20        | <b>Hyper activation of RAS signaling as a cancer treatment strategy</b><br><u>Matheus Henrique Dias</u> , Netherlands Cancer Institute, Amsterdam, Netherlands  |                  |
| 16:20 - 16:30        | <b>Q&amp;A and discussion</b>   |                  |
| <b>15:00 - 16:30</b> | <b>Type: Special session with Industry</b><br><b>Title: Hurdles in the regulatory and operational framework of early drug development in Europe</b><br>Moderation: Carolyn Britten, United States of America; Elena Garralda, Spain                               | <b>Scene AB</b>  |
| 15:00 - 15:15        | <b>How can Europe remain competitive</b><br><u>Carolyn Britten</u> , AMGEN (Headquarters) - USA, Thousand Oaks, United States of America  |                  |
| 15:15 - 15:30        | <b>Regulatory frameworks for biomarker-driven drug development</b><br><u>Francesco Pignatti</u> , European Medicines Agency - Amsterdam, Amsterdam, Netherlands   |                  |
| 15:30 - 15:45        | <b>The challenges of IVDR in Europe: Latest updates and potential solutions</b>   |                  |
| 15:45 - 16:00        | <b>Optimising the EU Clinical Trial Regulation and the Clinical Trials Information System to increase the attractiveness of the EU as a destination for clinical trials</b><br><u>Martin O'Kane</u> , Novartis Pharmaceuticals UK Limited, London, United Kingdom |                  |
| 16:00 - 16:30        | <b>Panel discussion</b>   |                  |
| <b>16:30 - 17:00</b> | <b>Type: Break</b><br><b>Title: Coffee break</b>  | <b>Foyer</b>     |
| <b>17:00 - 18:30</b> | <b>Type: Abstract session</b><br><b>Title: Abstract session 2</b>   | <b>Scene AB</b>  |



05.03.2025

**08:00 - 08:45**      **Type: Workshop**      **Loft GH**  
**Title: Workshop in collaboration with ESMO YOC: Evaluation of phase I data at the end of the study for next planning of drug development**  
 Moderation: Sophie Postel-Vinay, France; Jordi Rodon, United States of America

08:00 - 08:00      **YO Coordinators**  
Elene Mariamidze<sup>1</sup>, Rille Pihlak<sup>2</sup>, <sup>1</sup>Todua Clinic, Tbilisi, Georgia, <sup>2</sup>St. Bartholomew's Hospital - Barts Health NHS Trust, London, United Kingdom

08:00 - 08:10      **How do we pick a recommended dose: Safe may be, but optimised?**  
Sophie Postel-Vinay, Institut Gustave Roussy, Villejuif, France

08:10 - 08:20      **Early evaluation of efficacy in phase I trials: Persevere or halt the programme?**  
Jordi Rodon, The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America

08:20 - 08:45      **Q&A and discussion**

**08:45 - 10:15**      **Type: Special session with Industry**      **Scene AB**  
**Title: Fast tracking drug development by early screening for tumour-agnostic potential: Trialist, sponsor and regulator views**  
 Moderation: Fabrice André, France; Walter Bordogna, Switzerland

08:45 - 09:00      **The clinical/academia perspective**  
Lucinda Billingham, The Institute of Cancer and Genomic Sciences - University of Birmingham, Birmingham, United Kingdom

09:00 - 09:15      **The biotech perspective**  
Robert Doebele, Rain Oncology Inc, Newark, United States of America

09:15 - 09:30      **The pharma perspective**  
Walter Bordogna, F. Hoffmann-La Roche AG, Basel, Switzerland

09:30 - 09:45      **The regulator perspective**  
Harpreet Singh, Precision for Medicine, Bethesda, United States of America

09:45 - 10:15      **Panel discussion**

**08:45 - 10:15**      **Type: Educational session**      **Loft ABDE**  
**Title: Radiotheranostics**

08:45 - 09:05      **Molecular imaging to select patients for treatment with radiopharmaceuticals**  
Michael Hofman, Victorian Comprehensive Cancer Centre, Melbourne, Australia



09:05 - 09:25 **Navigating logistical challenges in radiopharmaceutical supply for treatments: Ensuring sufficient supply, durability and timely delivery from manufacture to infusion**  
Wim Oyen, Humanitas University, Pieve Emanuele, Italy

09:25 - 09:45 **Treatment with radiopharmaceutical targeting neuroendocrine cancers**  
Enrique Grande, MD Anderson Cancer Center Madrid, Madrid, Spain

09:45 - 10:05 **Novel targets and radiopharmaceuticals in early phase clinical development for radiotheranostics: Focus on FAP, integrins, and beyond**  
María De Miguel, CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, Spain

10:05 - 10:15 **Q&A and discussion**

**10:15 - 10:45** **Type: Break** **Foyer**  
**Title: Coffee break**

**10:45 - 12:15** **Type: Educational session** **Scene AB**  
**Title: Artificial intelligence (AI) in drug development**  
Moderation: Allan Jordan, United Kingdom; Bissan Al-Lazikani, United States of America

10:45 - 11:05 **Better trials, better drugs: Can AI help?**  
Allan Jordan, Sygnature Discovery Ltd, Nottingham, United Kingdom

11:05 - 11:25 **Big data and machine learning in drug discovery**  
Bissan Al-Lazikani, MD Anderson Cancer Center, Houston, United States of America

11:25 - 11:45 **Digital pathology for biomarker discovery**  
Anne Vincent-Salomon, Institut Curie, Paris, France

11:45 - 12:05 **The Virtual Child project**  
Amir Jassim, CRUK - Cancer Research UK Cambridge Institute - University of Cambridge, Cambridge, United Kingdom

12:05 - 12:15 **Q&A and discussion**

**10:45 - 12:15** **Type: Educational session** **Loft ABDE**  
**Title: New drugs for new targets**  
Moderation: Jordi Rodon, United States of America; Anastasios Stathis, Switzerland

10:45 - 11:05 **New conjugates for new targets: ADCs, ISACS, and others**  
Barbara Pistilli, Institut Gustave Roussy, Villejuif, Cedex, France

11:05 - 11:25 **YAP/TEAD inhibitors**  
Anastasios Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland





11:25 - 11:45 **Targeting MYC, targeting WNT, (...): What undruggables are left?**  
Cinta Hierro Carbo, Catalan Institute of Oncology (ICO- Badalona) Germans Trias i Pujol University Hospital, Badalona, Spain

11:45 - 12:05 **Drugs for new synthetic lethality scenarios: WRN and MTAP**  
Pooja Shah, The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America

12:05 - 12:15 **Q&A and discussion**

12:15 - 13:15 **Type: Break** **Foyer**  
**Title: Lunch**

12:30 - 13:15 **Type: Workshop** **Loft GH**  
**Title: Workshop in collaboration with ESMO YOC: Patient participatory research**  
Moderation: Helen Bulbeck, United Kingdom; Lesley Seymour, Canada

12:30 - 12:30 **YO Coordinators**  
Elene Mariamidze<sup>1</sup>, Rille Pihlak<sup>2</sup>, <sup>1</sup>Todua Clinic, Tbilisi, Georgia, <sup>2</sup>St. Bartholomew's Hospital - Barts Health NHS Trust, London, United Kingdom

12:30 - 12:40 **Early clinical trials: What are the most important questions that patients need to have addressed?**  
Helen Bulbeck, brainstrust - the brain cancer people, Cowes, United Kingdom

12:40 - 12:50 **Improving patient participatory research in early clinical trials: Successes and where we can do better**  
Lesley Seymour, Canadian Cancer Trials Group, Kingston, Canada

12:50 - 13:15 **Q&A and discussion**

13:15 - 14:45 **Type: Special session with Industry** **Scene AB**  
**Title: The corporate and investor mindset: What types of anti-cancer drugs and clinical research proposals will be prioritised in the near term?**

13:15 - 13:30 **The large pharma perspective**  
Cristian Massacesi, AstraZeneca Pharmaceuticals LP, Gaithersburg, United States of America

13:30 - 13:45 **The small company perspective**  
Laura Soucek, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Spain

13:45 - 14:00 **Regulatory and market access challenges in oncology drug development**  
Shaily Arora, AstraZeneca Pharmaceuticals LP, Gaithersburg, United States of America



14:00 - 14:15 **The investor perspective**  
Yael Gruenbaum Cohen, aMoon Ventures Sh.Y.Ltd, Ra'anana, Israel

14:15 - 14:45 **Panel discussion**

**13:15 - 14:45** **Type: Educational session** **Loft ABDE**  
**Title: Novel combinations**  
Moderation: Daniel Shao Weng Tan, Singapore

13:15 - 13:35 **Evolving combinations: 'Second generation' IO checkpoints**  
Emanuela Romano, Institut Curie, Paris, France

13:35 - 13:55 **Next frontiers of ADCs combinations**  
Daniel Shao Weng Tan, NCCS - National Cancer Centre Singapore, Singapore, Singapore

13:55 - 14:15 **Therapeutic potential of harnessing NK cells**  
Eric Vivier, Aix-Marseille University - Faculté de Médecine - Timone, Marseille, France

14:15 - 14:35 **Therapeutic vaccine and immunotherapy: Key considerations**  
Caroline Even, Institut Gustave Roussy, Villejuif, Cedex, France

14:35 - 14:45 **Q&A and discussion**